Chat with this insight
Save time and jump to the most important pieces.
Recent Analyst Ratings for $NPCE
Date | Price Target | Rating | Analyst |
---|---|---|---|
1/21/2025 | $17.00 | Buy | UBS |
3/14/2024 | $16.00 → $20.00 | Equal Weight → Overweight | Wells Fargo |
1/30/2024 | $22.00 | Outperform | Leerink Partners |
11/10/2023 | $11.00 | Overweight | Cantor Fitzgerald |
8/24/2023 | $5.00 → $6.00 | Underweight → Equal-Weight | Morgan Stanley |
2/22/2023 | $10.00 | Buy | Lake Street |
4/6/2022 | $13.00 | Outperform | Wolfe Research |
3/11/2022 | $11.00 → $9.00 | Equal-Weight | Wells Fargo |
NeuroPace to Present at the 24th Annual Needham Virtual Healthcare Conference
MOUNTAIN VIEW, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will present at the 24th Annual Needham Virtual Healthcare Conference at 3:00pm ET (12:00pm PT) on Tuesday, April 8, 2025. Management will also host investor meetings during the conference. The presentation will be accessible via live webcast here. A webcast replay will be available for 90 days following the presentation in the Events section of NeuroPace's Investor website at https://investors.neuropace.com. About NeuroPace, Inc. Based in Mountain View, Calif., NeuroPac
NeuroPace Reports Fourth Quarter and Full Year 2024 Financial Results
-- Record quarterly revenue of $21.5 million in Q4 2024 -- -- Full-year 2025 revenue guidance of $92 to $96 million -- -- Completed an underwritten public offering of $74.8 million, using $49.5 million of the net proceeds to repurchase 100% of KCK holdings and $20.2 million to strengthen its balance sheet to support planned operations to reach cash flow breakeven -- -- Management scheduled to host a conference call today at 4:30 p.m. ET -- MOUNTAIN VIEW, Calif., March 04, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported financial results for the fourth quarter and full year
UPDATE – NeuroPace to Present at the Leerink Partners Global Healthcare Conference
MOUNTAIN VIEW, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will present at the Leerink Partners 2025 Global Healthcare Conference at 4:20pm ET (1:20pm PT) on Monday, March 10, 2025, in Miami, FL. Management will also host investor meetings during the conference. The presentation will be accessible via live webcast here. A webcast replay will be available for two weeks following the presentation in the Events section of NeuroPace's Investor website at https://investors.neuropace.com. About NeuroPace, Inc. Based in Mountain View,
UBS initiated coverage on NeuroPace with a new price target
UBS initiated coverage of NeuroPace with a rating of Buy and set a new price target of $17.00
NeuroPace upgraded by Wells Fargo with a new price target
Wells Fargo upgraded NeuroPace from Equal Weight to Overweight and set a new price target of $20.00 from $16.00 previously
Leerink Partners initiated coverage on NeuroPace with a new price target
Leerink Partners initiated coverage of NeuroPace with a rating of Outperform and set a new price target of $22.00
CHIEF MEDICAL OFFICER Morrell Martha was granted 11,700 shares, increasing direct ownership by 15% to 90,926 units (SEC Form 4)
4 - NeuroPace Inc (0001528287) (Issuer)
CHIEF FINANCIAL OFFICER Kuhn Rebecca was granted 11,700 shares, increasing direct ownership by 9% to 136,595 units (SEC Form 4)
4 - NeuroPace Inc (0001528287) (Issuer)
CHIEF EXECUTIVE OFFICER Becker Joel covered exercise/tax liability with 4,506 shares and was granted 58,500 shares, increasing direct ownership by 103% to 106,464 units (SEC Form 4)
4 - NeuroPace Inc (0001528287) (Issuer)
SEC Form S-8 filed by Neuropace Inc.
S-8 - NeuroPace Inc (0001528287) (Filer)
SEC Form 10-K filed by Neuropace Inc.
10-K - NeuroPace Inc (0001528287) (Filer)
Neuropace Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - NeuroPace Inc (0001528287) (Filer)
NeuroPace Continues to Strengthen Management Team
MOUNTAIN VIEW, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced the appointment of Amy Treadwell as its new Vice President of Human Resources, effective immediately. "We are excited to have Amy join the team and help us continue to build an engaged, high-performing culture that supports our growth," said Joel Becker, Chief Executive Officer of NeuroPace. "We are at an important point in our growth with a number of significant commercial, operating, and technological opportunities in front of us. We believe Amy's appointment, along with the recent appointments
NeuroPace Strengthens Management Team with Two Key Appointments
Appointed former key developer of RNS System as new Vice President of Research and Development Appointed former head of commercial marketing for Boston Scientific's DBS franchise as the new Vice President of Marketing MOUNTAIN VIEW, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced the appointments of Brett Wingeier as the new Vice President of Research and Development and Katie Keller as the new Vice President of Marketing, effective immediately. "We are excited to welcome Katie and Brett to our team. Katie brings an understanding of the neurostimulation ma
NeuroPace Announces CEO Transition
NeuroPace Appoints Joel Becker as President & CEO Becker Brings a Track Record of Strong Commercial Execution and Deep Medical Device Operating Expertise Mike Favet to leave Company after four years as President, CEO and Board Member and will continue to advise through transition MOUNTAIN VIEW, Calif., June 28, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ:NPCE), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced the appointment of Mr. Joel Becker as NeuroPace President & CEO and member of the Board of Directors effective July 10, 2023. Mr. Michael Favet will be stepping down as CEO and as a member of NeuroPace'
NeuroPace to Report Fourth Quarter and Full Year 2024 Financial Results on March 4, 2025
MOUNTAIN VIEW, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the fourth quarter and full year of 2024 after market close on Tuesday, March 4, 2025. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at https://viavid.webcasts.com/starthere.jsp?ei=1706647&tp_key=43fdbb668b. Individuals interested in participating in the cal
NeuroPace Reports Third Quarter 2024 Financial Results and Increases 2024 Revenue Guidance
-- Grew revenue 28% year-over-year to $21.1 million in Q3 2024 -- -- Increased full-year 2024 revenue guidance to $78 million to $80 million -- -- Demonstrated continued operating discipline through further decrease in cash burn -- -- Management scheduled to host a conference call today at 4:30 p.m. ET -- MOUNTAIN VIEW, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported financial results for the third quarter ended September 30, 2024, and provided a corporate update. Recent Highlights Reported record revenue of $21.1 million in the third quarter of 2024, a 2
NeuroPace to Report Third Quarter 2024 Financial Results on November 12, 2024
MOUNTAIN VIEW, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (NASDAQ:NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the third quarter of 2024 after market close on Tuesday, November 12, 2024. The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at https://viavid.webcasts.com/starthere.jsp?ei=1690707&tp_key=080b652fbc. Individuals interested in participating in the call via telep
Amendment: SEC Form SC 13G/A filed by Neuropace Inc.
SC 13G/A - NeuroPace Inc (0001528287) (Subject)
Amendment: SEC Form SC 13G/A filed by Neuropace Inc.
SC 13G/A - NeuroPace Inc (0001528287) (Subject)
Amendment: SEC Form SC 13G/A filed by Neuropace Inc.
SC 13G/A - NeuroPace Inc (0001528287) (Subject)